Infectious Diseases Research

Below are current clinical trials.

273 studies in Infectious Diseases Research
(all studies, either open or closed).

Filter this list of studies by location, status and more.

1. A Study of Inhaled Molgramostim in Cystic Fibrosis Subjects with Nontuberculous Mycobacterial (NTM) Infection

   Rochester, Minn.

   The purpose of this study is to evaluate the effectiveness of inhaled molgramostim, administered open-label, to adult cystic fibrosis subjects with chronic pulmonary nontuberculous mycobacterial (NTM) infection, with or without ongoing antimycobacterial guideline based combination therapy.

2. Prevalence and Predictors of Spike Protein Antibodies in COVID-19 Vaccinated Individuals

   Jacksonville, Fla.

   The objectives of this study are to determine the prevalence of spike (S) protein antibodies in COVID-19 vaccinated individuals, to assess the role of age and gender in relation to the capacity of COVID-19 vaccinated individuals to develop S protein antibodies, and to identify microRNA (miRNA) in serum derived exosomes that correlates with S protein antibody development and determine how age and gender may affect the correlation B.

3. A Study to Evaluate Filter Comparison for Reducing COVID-19 Infection Risk

   Rochester, Minn.

   The purpose of this study is to compare cardiopulmonary exercise testing with no filter to pre- and post-flow sensor placement.

4. Extent of Donor Site Morbidity after Scaphoid Repair Surgery Using the Medial Femoral Condyle

   Rochester, Minn.

   The purpose of the study is to determine the extent of donor site morbidity after harvesting the medial femoral condyle for scaphoid nonunion treatment. The outcomes being measured are: superficial infection, deep infection, pain (short term), pain (long term), knee function and quality of  scar.

5. Study of Efficacy and Safety of Grazoprevir (MK-5172) + Elbasvir (MK-8742) With or Without Ribavirin for Participants With Hepatitis C Genotype 1, 4, or 6 Infections Who Have Failed Prior Treatment With Pegylated Interferon + Ribavirin (MK-5172-068)

   Scottsdale/Phoenix, Ariz.

   This is an efficacy and safety study of grazoprevir (MK-5172) in combination with elbasvir (MK-8742) with or without ribavirin (RBV) in participants with chronic hepatitis C virus (HCV) genotype (GT) 1, 4, or 6 infections who have failed prior therapy with pegylated interferon and RBV. The primary study hypothesis is that in at least one of the study arms, the percentage of participants achieving sustained viral response 12 weeks after the end of all study treatment (SVR12) will be superior to 58%.

6. Immunological Consequences of COVID-19 Vaccination in Patients with Rheumatic Diseases

   Rochester, Minn.

   This research trial will study the immune respone to COVID-19 vaccination in patients with rheumatic diseases.

7. A Study to Establish a Registry of Post-COVID Investigations, Education and Symptom Management

   Rochester, Minn.

   The purpose of this study is to establish a registry that will follow patients that are seen in the PCCOC clinic with Post-COVID symptoms that persist for greater than 28 days. 

8. A Study to Analyze Potential Long-term Treatments for Covid-19 Recovery

   Rochester, Minn., Scottsdale/Phoenix, Ariz.

   This study aims to further understand the extent of long term effects of COVID-19 via batteries of self-assessment questionnaires focused on the most common complications of SARS-COVID 19 infections including respiratory and cardiovascular symptoms, frailty, fatigue, exercise capacity, cognitive and emotional functionality, and overall quality of life. Furthermore, we will investigate the impact of 4 weeks of respiratory muscle training and nasal breathing on the above mentioned long-term Covid-19 disease complications.

    

9. A Study to Evaluate COVID19 Pregnancy Risks

   Rochester, Minn.

   It is unclear if and how COVID19 can be passed from mother to child. Therefore, we aim to collect maternal and fetal samples from COVID19-infected pregnant women and compare them to pregnant women who have clinical indications for COVID 19 testing at the time of hospital admission but end up being COVID19- (control group). Pregnant women who are either COVID19+ or COVID19- with symptoms will be followed during this study. Our objective is to understand the prevalence of maternal fetal transmission, risk factors and outcomes of a COVID19+ pregnancy, and how the virus can be passed from mother to baby in the population of Mayo Clinic patients. 

10. Open-Label Extension of CP101 Trials Evaluating Oral Full-Spectrum Microbiota™ (CP101) in Subjects With Recurrence of Clostridium Difficile Infection

    Scottsdale/Phoenix, Ariz.

    The purpose of this open-label extension of CDI-001 (subsequently referred to as PRISM 3) is to evaluate the safety and efficacy in reducing recurrence of CDI in adults who had a recurrence within 8 weeks of receiving CP101 or placebo in PRISM 3. Subjects who are experiencing recurrent CDI will undergo screening procedures. Subjects who meet eligibility criteria will be eligible to be enrolled in the extension study and administered CP101. Approximately 70 subjects will receive CP101. The treatment duration will be 1 day. Subjects will be monitored for recurrence of CDI, safety, and tolerability for 24 weeks following receipt of CP101. The primary efficacy and safety endpoints will be evaluated at 8 weeks post treatment, and all subjects will continue to be followed for an additional 16 weeks for safety and recurrence of CDI.